ARTICLE | Clinical News
Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain
August 16, 2018 9:24 PM UTC
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to treat chronic pain caused by osteoarthritis of the knee or hip. Fasinumab is a mAb against nerve growth factor (NGF).
Regeneron gained $9.91 to $371.78 on Thursday, for a gain of over $1 billion in market cap...
BCIQ Target Profiles